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Abstract
Background: Arsenic trioxide (ATO) is approved for treating terminal-stage liver cancer in China. Cryptotanshinone
(CT), a STAT3 inhibitor, has exhibited certain anti-tumor potency; however, the use of CT enhanced ATO for treating
liver cancer has not been reported. Here we try to elucidate how CT could enhance the efficacy of ATO for treating
liver cancer and its correlation to STAT3 in vitro and in vivo.
Methods: Cell viability of ATO combined with CT was assessed by 1MTT assay. Cell apoptosis induced by ATO
combined with CT was detected by Annexin V/PI staining and apoptosis-related proteins were detected by western
blotting. STAT3-related proteins were analysis by western blotting analysis and Immunofluorescence assays. Efficacy
evaluation of ATO combined with CT on xenograft was carried in nude mice and related proteins were analysis by
Immunohistochemistry assays.
Results: First we evaluated cell vitality, and our data indicated that the ATO combined with CT showed obvious
growth inhibition of Bel-7404 cells compared to ATO or CT alone. Next we found that ATO combined with CT
induced cell apoptosis in Bel-7404 cells and upregulated the activation of apoptosis-related proteins cleaved-
caspase-3, cleaved-caspase-9, and cleaved-poly(ADP-ribose) polymerase in a time-dependent manner. Next, we
found that ATO combined with CT not only inhibited the constitutive levels of phosphorylated-JAK2 and
phosphorylated-STAT3Tyr705 but did so in a time-dependent manner. We also found that ATO combined with CT
reversed the upregulated expression of phosphorylated-STAT3Tyr705 stimulated by interleukin-6 and downregulated
STAT3 direct target genes and the anti-apoptotic proteins Bcl-2, XIAP, and survivin but obviously upregulated the
promoting apoptosis proteins Bak,.In vivo studies showed that ATO combined with CT decreased tumor growth.
Tumors from ATO combined with CT–treated mice showed decreased levels of phosphorylated-STAT3Tyr705 and the
anti-apoptotic protein Bcl-2 but an increased level of pro-apoptotic protein Bax.
Conclusions: Our study provides strong evidence that CT could enhance the efficacy of ATO in treating liver
cancer both in vitro and in vivo. Downregulation of phosphorylated-STAT3 expression may play an important role
in inducing apoptosis of Bel-7404 cells.
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Background
Primary hepatocellular carcinoma (HCC) is one of the
most common malignancies worldwide [1], but only 10–
30% of patients are surgical candidates [2]. Chemother-
apy is a major terminal-stage liver cancer treatment, but
the existing chemotherapy regimens have problems such
as a poor curative effect and adverse reactions. There-
fore, the identification of new treatment methods to im-
prove survival rates is a critical need.
Arsenic trioxide (ATO), a major component of trad-
itional Chinese medicine, was first used to treat acute
promyelocytic leukemia. Some researchers propose that
ATO activates the caspase cascade and induces produc-
tion of reactive oxygen species, resulting in apoptosis
[3]. Although low-dose ATO was granted approval by
the National Drug Administration in China in 2004 for
treating terminal-stage liver cancer, it failed to show a
therapeutic effect at an endurable dose in a recent
phase II clinical trial [4]. The ATO antitumor effect on
liver cancer and glioma solid tumors has been clarified
in vivo and in vitro [5, 6]. ATO was shown to lead the
mitochondrial permeability transport hole open, cyto-
chrome C release involved in mitochondrial apoptosis
pathway. However, the tumor cells of the ERK and AKT
pathways as well as nuclear factor-kappaB (NF-ĸβ) and
abnormal STAT3 kinase activation, resulting in decreased
ATO drug sensitivity [7–9]. Furthermore, some scholars
considered using ATO with other drugs to enhance its an-
titumor effect. The co-treatment of oridonin and As2O3
induced reactive oxygen species–mediated downregula-
tion of Akt and XIAP and inhibited NF-ĸβ activation in
HCC cells (Chen et al, [9]). Genistein synergized with a
low dose of ATO (2.5 mg/kg) inhibit the growth of HepG2
tumors, by downregulating Bcl-2 expression, upregulating
Bax expression, enhancing the activation of caspase-9 and
-3, and increasing the release of cytochrome c [10].
Metformin enhanced both the proliferation-inhibiting and
apoptosis-inducing effects of ATO on the HepG2 and
Bel7402 HCC cell lines by involving metformin-induced
downregulation of Bcl-2 [11].
To enhance the efficacy of ATO in treating liver cancer,
we focus on cryptotanshinone (CT), a major tanshinone
isolated from Salvia miltiorrhiza that has been used for
the treatment of coronary artery disease, hyperlipidemia,
acute ischemic stroke, and Alzheimer’s disease [12–14].
CT has confirmed ability to inhibit STAT3 phosphoryl-
ation [15, 16]. Several groups recently reported that CT
could arrest the cell cycle and induce apoptosis in several
cancer cell lines [17–19]. CT can inhibit the viability of
human SMMC-7721 hepatoma cells, which is related to
the reduced expression of MAP2K1 mRNA [20].
Cryptotanshinone has also demonstrated sensitizing
effects to a broad range of anti-cancer agents including
Fas/Apo-1, tumor necrosis factor-α, cisplatin, etoposide,
and 5-FU by inducing ER stress, highlighting its thera-
peutic potential in the treatment of human hepatoma
and breast cancer (Park et al. [19]).
Aberrant activation of JAK/STAT3 signaling has been
found in many tumors [21–23]. In particular, STAT3
participates in the initiation, development, and progres-
sion of human cancers by inducing STAT3 downstream
genes that encode anti-apoptotic proteins, cell cycle reg-
ulators, and angiogenic factors such as Bcl-xl and cyclin
D1 [24, 25]. Cytokines of the interleukin-6 (IL-6) family,
including IL-6, are potent activators of the JAK/STAT3
pathway and predominantly activate STAT3 via JAK1
and JAK2. IL-6 caused STAT3 kinase activation, result-
ing in anti-apoptotic Bcl-2 expression and inhibiting of
apoptosis proteins such as Bcl-xl and Mcl-1. The inhib-
ition of constitutive STAT3 activation in malignant cells
can suppress Bcl-xl and Mcl-1 genes [26].
According to the above results, we hypothesized that
CT could enhance the efficacy of ATO for treating liver
cancer and that phosphorylated-STAT3 may play a key
role. Here we try to elucidate how CT could enhance the
efficacy of ATO for treating liver cancer and its correl-
ation to STAT3 in vitro and in vivo. Our research aimed




The Bel-7404 gastric cancer cell line was obtained from
the Center Laboratory of Zhejiang Provincial Hospital of
TCM, China, and cultured in RPMI-1640 supplemented
with 10% fetal bovine serum.
Reagents
Hematoxylin and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphe-
nyl-2-H-tetrazolium bromide (MTT) were purchased from
Sigma. Arsenic trioxide for injection was purchased from
Double Heron Pharmaceutical Co., LTD. Cryptotanshinone
was purchased from Chengdu Must, Bio-technology
Co., LTD. Antibodies against cleaved-caspase-3,
cleaved-caspase-9, cleaved poly(ADP-ribose) polymer-
ase, Bax, Bak, XIAP, Mcl-1, Bcl-2, Bcl-xl, survivin,
phosphorylated-JAK2, and phosphorylated-STAT3Tyr705
were purchased from Cell Signaling Technology, while
β-actin antibody was purchased from Sigma-Aldrich.
An Annexin V/PI binding kit was purchased from
Santa Cruz Biotechnology, Inc. RIPA Lysis Buffer and a
BCA Protein Assay Kit were purchased from Beyotime.
Immobilon ECL was purchased from Millipore. Rhodamin-
labeled goat anti-mouse immunoglobulin G (IgG) and
DAPI were obtained from Hangzhou Dawei Biotech
Co., LTD.
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Cell viability analysis
The cells were plated in 96-well plates (3000–4000 cells/
well) in triplicate, incubated overnight, and treated with
different concentrations of CT (10 μM, 20 μM), ATO
(1 μM, 2 μM), or CT (10 μM, 20 μM) combined with
ATO (1 μM, 2 μM) for 24 h, and then cell viability was
assessed by MTT assay. Briefly, 20 μL of MTT 5 mg/mL
was added to each cell plate and the cells were incubated
for 4 h. The medium was then removed and 150 μL of
dimethylsulfoxide was added. The absorbance was then
detected at 490 nm using an enzyme standard instru-
ment (BioTek). Cell viability was normalized to that of
untreated cells.
Annexin V/PI staining to detect apoptosis
Bel-7404 were divided into four groups (5 × 105 cells
each): control, CT, ATO, and CT combined with ATO.
After treatment for 24 h, apoptosis was detected using the
Annexin V/PI binding kit and then analyzed by a Fluores-
cence Activated Cell Sorter(FACS Calibur; BD Biosci-
ences). The experiments were performed in triplicate.
Western blotting analysis
Total protein was isolated using RIPA Lysis Buffer, and
the concentrations were measured using the BCA Protein
Assay Kit. Proteins (30 μg) were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis with
10% separation gels and then transferred to polyvinylidene
fluoride membranes. The membranes were blocked by 5%
non-fat milk in Tris-buffered saline with Tween-20 (0.01%
Tween) for 1 h, incubated with primary antibodies over-
night at 4 °C, followed by a 1-h incubation with horserad-
ish peroxidase–conjugated secondary antibodies and then
developed with Immobilon enhanced chemiluminescence
(ECL) [27].
Immunofluorescence assays
Cells were treated for 24 h and immunofluorescence
staining was performed as previously described [28]. We
used the primary antibodies and rhodamine-labeled goat
anti-mouse IgG as mentioned above. The nuclei were
stained with 4,6-diamino-2-phenyl indole(DAPI) 1 mg/
mL for 30 min. Fluorescent images were acquired with a
laser scanning confocal microscope (Leica).
Animals
Forty 5-week-old-male BALB/c nude (weight, 20 ± 2 g)
were obtained from Shanghai Super B&K Laboratory Ani-
mal Corp. Ltd. and raised in the Zhejiang Chinese Medical
University Animal Experiment Research Center. Five mice
were housed per standard cage in a room maintained at
constant temperature and humidity with a 12-h light:dark
cycle. The mice were fed a regular sterilized chow diet
with water. A laboratory animal management and welfare
ethical review was performed by the Laboratory Animal
Management and Ethics Committee of Zhejiang Chinese
Medical University (ZSLL-2013-019).
ATO combined with CT treatment of xenograft tumors
Bel-7404 cells were harvested from subconfluent cul-
tures, washed once in serum-free medium, and resus-
pended in phosphate-buffered saline (PBS). Bel-7404
cells (5.0 × 106) in 200 μL of PBS were injected into the
axillary back area under the skin of BALB/C nude mice.
When the tumors reached approximately 100 mm3, the
nude were randomly divided into four groups: control
(normal saline, once daily, intraperitoneal [ip] injection),
ATO (2.5 mg/kg, once daily, ip injection), CT (100 mg/kg,
once daily, ip injection), and ATO (2.5 mg/kg, once daily,
ip injection) combined with CT (100 mg/kg, once daily, ip
injection). The tumors were measured twice weekly by a
vernier caliper and the tumor volume computation for-
mula was V = a × b2 × π/6, where V indicated approximate
tumor volume, a indicated the tumor’s long diameter, and
b indicated the tumor’s short diameter. The mice were
euthanized on the second day after 19 days of treatment.
Each tumor excised from the mice was weighted and
divided into two parts. One part of the tumor tissue was
formalin-fixed, while another part was snap-frozen in li-
quid nitrogen and stored at −80 °C. The tumor inhibition
rate (%) was calculated as (1 - average tumor weight of
treatment group/the average tumor weight of control
group) × 100%.
Immunohistochemistry assays
In brief, the tissue sections were deparaffinized in xylene,
rehydrated with ethanol, hot-repaired by high pressure,
and blocked by 30% H2O2. Next, the tissue sections were
incubated with primary antibody (phosphorylated-STAT3-
Tyr705, Bcl-2, and Bax antibodies) overnight at 4 °C (the
PBS was replaced with primary antibody in the negative
immunohistochemistry control), and then stained with
secondary antibody for 1 h at room temperature. The per-
oxidase reaction was developed with diaminobenzidine
and the slides were counterstained with hematoxylin.
Statistical analysis
Data are presented as mean ± standard deviation (SD)
derived from at least three independent experiments.
The data were analyzed by one-way analysis of variance
followed by the post hoc least significant differences test.
P-values < 0.05 were considered statistically significant.
Results
ATO combined with CT inhibited Bel-7404 cell growth
Bel-7404 cells were treated with ATO (1 μM, 2 μM), CT
(10 μM, 20 μM), or ATO combined with CT for 24 h,
and then cell viability was assessed by MTT assay. Cell
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viability was normalized to control cells. ATO combined
with CT treatment had an obvious dose-dependent
growth inhibition effect on Bel-7404 cells compared to
ATO or CT treatment alone (Fig. 1).
ATO combined with CT induced liver cancer cell
apoptosis
Annexin V/PI staining was used to investigate whether
ATO combined with CT can induce cell apoptosis in Bel-
7404 cells. We found that apoptosis was induced by 13.8%
ATO (2 μM), 3.6% CT (20 μM), and 45.6% ATO com-
bined with CT (Fig. 2a). Next, we use the western blot
method to detect the apoptosis-related proteins cleaved-
caspase-3, cleaved-caspase-9, and cleaved-PARP. We
found that, although ATO or CT alone had little effect on
the activation of cleaved-caspase-3, cleaved-caspase-9, and
cleaved-PARP, that of the combined treatment group was
highly increased (Fig. 2b). To explore whether this in-
crease was time-dependent, the cells were treated with
ATO combined with CT for the indicated time. We found
that ATO combined with CT increased the expression of
all three proteins in a time-dependent manner (Fig. 2c).
ATO combined with CT inhibited both endogenous
constitutive and Il-6-induced STAT3 activation in Bel
-7404 cells
Aberrant activation of JAK/STAT3 signaling has been
found in many tumors (Zhang et al. [21]-Hu et al. [23]).
To examine whether ATO combined with CT–induced
liver cancer cell apoptosis was related to the JAK/
STAT3 signaling pathway, we detected the expressions
of phosphorylated-JAK2 and phosphorylated-STAT3-
Tyr705. We found that the combination group not only
inhibited the constitutive levels of phosphorylated-
JAK2 and phosphorylated-STAT3-Tyr705 but did so in a
time-dependent manner (Figs. 3a, b). Furthermore, we
employed laser scanning confocal microscopy method
as a qualitative assay to investigate the effect of ATO
combined with CT on phosphorylated-STAT3-Tyr705 ex-
pression. The nuclei were stained with DAPI (blue),
while the phosphorylated-STAT3-Tyr705 was stained
with anti-phosphorylated- STAT3-Tyr705 antibody
followed by rhodamine-conjugated antibody (red). We
found that the expression of phosphorylated-STAT3-
Tyr705 influenced by ATO combined with CT was also
decreased (Fig. 3c). Studies have shown that cytokines
of the IL-6 family, including IL-6, was potent activators
of JAK/STAT3 pathway, predominantly activating
STAT3 through JAK1 and JAK2 [29]. we evaluated
whether ATO combined with CT would affect this
signal transduction pathway. As shown in Fig. 3d,
phosphorylated-STAT3-Tyr705 was upregulated when
stimulated by IL-6 10 ng/mL (R&D Systems Inc.) for
4 h. However, this effect was reversed by ATO com-
bined with CT treatment.
To determine whether STAT3 phosphorylation inhib-
ition affected STAT3 target gene expression, we analyzed
the expression of selected STAT3 direct target genes.
Anti-apoptotic proteins such as Bcl-2, XIAP, survivin,
Bcl-xl and the promoting apoptosis proteins Bak was
detected by immunoblots. We found that, compared to
the control group, the combination group significantly
downregulated the expression of anti-apoptotic proteins
Bcl-2, XIAP, and survivin but obviously upregulated the
pro-apoptosis proteins Bak, whereas Bcl-xl expression
had no obvious changes (Fig. 3e, f ). We also found that
ATO combined with CT regulated apoptosis- related
proteins in a time-dependent manner (Fig. 3g, h). All of
these results indicate that phosphorylated-STAT3 played
a key role in ATO combined with CT–induced liver can-
cer cell apoptosis.
ATO combined with CT inhibited xenograft tumor growth
on nude mice
To determine the effect of ATO combined with CT on
tumor growth in vivo, we employed the subcutaneous Bel-
7404 tumor model. The tumors were randomly assigned
into four groups. Tumor volumes were measured every 3–
4 days and the excised tumors were weighed at the end of
the day. Overall, the results showed a gradual increase in
tumor volume in every group. However, compared to the
control group, the volumes in the remaining groups tended
Fig. 1 Cell viability analysis. The cell vitality testing of (ATO combined
with CT on Bel-7404 cells. The cells were divided into control, CT
(10 μM, 20 μM), ATO (1 μM, 2 μM), and CT (10 μM, 20 μM) combined
with ATO (1 μM, 2 μM) groups and treated for 24 h and their vitality
was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-
tetrazolium bromide assays. Each experiment was done in triplicate
and the results were averaged. The data represent mean ± SD of
triplicate samples from a representative experiment of three
independent experiments. *P < 0.05 vs. control; #P < 0.05 ATO + CT
vs. ATO; ΔP < 0.05 ATO + CT vs. CT
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to increase slowly. On days 14, 17, and 19, the differences
between the control group and the other groups were sig-
nificant. Meanwhile, the combination group presented the
slowest growth rate (Fig. 4a). The excised tumors were
weighed. Five mice were randomly selected from each
group and photographed using a digital camera (Fig. 4b).
The tumor weights in the treatment groups were signifi-
cantly smaller than those of the control group (P < 0.01),
while those of the combination group were significantly
smaller than those of the ATO (P < 0.01) and CT (P < 0.01)
groups (Fig. 4c). We next investigated the expression of
phosphorylated-STAT3-Tyr705 and the related apoptotic
protein Bcl-2 and Bax by immunohistochemistry. Our ana-
lyses revealed that tumors from the ATO combined with
CT group had decreased levels of phosphorylated-STAT3-
Tyr705 as well as of the anti- apoptotic protein Bcl-2 com-
pared to the control group. However, the levels of pro-
apoptotic protein Bax were significantly increased in the
ATO combined with CT group (Fig. 4d, e).
Discussion
HCC is the most common liver malignancy and a major
health problem globally. Targeted therapy of the signal trans-
duction pathway in human malignancies is a recent
approach that has shown great promise when used alone or
combined with conventional therapies [30]. Here we clarified
that CT could enhance the efficacy of ATO in treating liver
cancer and that phosphorylated-STAT3 may play a key role.
The use of ATO has been considered with other drugs
to enhance its antitumor effect [9–11, 31]. To see whether
ATO combined with CT inhibited Bel-7404 cell growth,
we first evaluated cell vitality when Bel-7404 cells were
treated with different concentrations of ATO or CT. Our
data indicated that ATO combined with CT treatment
showed obvious growth inhibition compared to the use of
ATO or CT alone in a dose-dependent manner.
We then found that ATO combined with CT could in-
duce cell apoptosis rates in Bel-7404 cells and upregulate
the activation of apoptosis-related proteins cleaved-
caspase-3, cleaved-caspase-9, and cleaved-PARP in a time-
dependent manner. These results supported our initial
hypothesis that CT could enhance the efficacy of ATO for
treating liver cancer. These results were consistent with
those of the above reports [9, 10].
As a STAT3 inhibitor, CT has confirmed ability to in-
hibit STAT3 phosphorylation activity [15, 16]. STAT3 par-
ticipates in the initiation, development, and progression of
human cancers via inducing downstream genes that en-
code anti-apoptotic proteins, cell cycle regulators, and
Fig. 2 ATO combined with CT induced liver cancer cell apoptosis. a Bel-7404 cells were divided into four groups (control, CT, ATO, CT combined
with ATO). After 24-h treatment, the cells were stained using an Annexin V/PI binding kit and then analyzed by a FACS flow cytometer. b Cells
were treated for 24 h, and whole-cell extracts were prepared and analyzed by western blot using antibodies against cleaved-caspase-3, cleaved-
caspase-9, and cleaved-PARP. c The cells were treated with ATO combined with CT for the indicated times and the expressions of cleaved-caspase-3,
cleaved-caspase-9, and cleaved-PARP were analyzed by western blotting. The experiments were performed in triplicate
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angiogenic factors such as Bcl-xl and cyclin D1 [17–19].
Next we found that ATO combined with CT not only
inhibited the constitutive levels of phosphorylated-JAK2
and phosphorylated- STAT3-Tyr705 but did so in a time-
dependent manner. We also found that ATO combined
with CT reversed the upregulated expression of
phosphorylated-STAT3-Tyr705 stimulated by IL-6 and
downregulated STAT3 direct target anti-apoptotic pro-
teins Bcl-2, XIAP, and survivin while obviously upregulat-
ing the pro-apoptotic proteins Bak in Bcl-7404 cells.
Fig. 3 ATO combined with CT inhibited both endogenous constitutive and Il-6–induced STAT3 activation in Bel-7404 cells. a Bel-7404 cells were
divided into four groups (control, CT, ATO, and CT combined with ATO) and treated for 24 h, while whole-cell extracts were prepared and analyzed by
western blotting using antibodies against phosphorylated-JAK2 and phosphorylated-STAT3-Tyr705. b Cells were treated with ATO combined with CT for
the indicated times and the expressions of phosphorylated-JAK2 and phosphorylated-STAT3-Tyr705 were detected by western blotting. c Laser scanning
confocal microscopy was used to investigate the effect of ATO combined with CT on phosphorylated-STAT3-Tyr705 expression a 4 h. The
nuclei were stained with DAPI (blue), while phosphorylated-STAT3-Tyr705 was stained with anti-phosphorylated-STAT3-Tyr705 antibody followed
by rhodamine-conjugated antibody (red). d ATO combined with CT reversed the interleukin-6–induced phosphorylated-STAT3-Tyr705 upregulation
(×800). e, g STAT3 direct target genes such as anti-apoptotic protein and promoting apoptosis proteins were detected by western blotting and the
time-dependent relationships were detected. f, h Desnisity were measured by quantity one. The bar graphs were drawn based on the relative density
Shen et al. BMC Complementary and Alternative Medicine  (2017) 17:106 Page 6 of 9
These results suggest that phosphorylated-STAT3 plays an
important role in the ATO enhanced CT–induced liver
cancer cell apoptosis in vitro and that downregulating
phosphorylated-STAT3 may be key.
Finally, we employed the subcutaneous Bel-7404 tumor
model. Our in vivo studies showed that CT enhanced the
effect of ATO in reducing tumor growth. Tumors from
ATO combined with CT-treated mice showed decreased
levels of phosphorylated- STAT3-Tyr705 and the anti-
apoptotic protein Bcl-2, while levels of the pro-apoptotic
protein Bax was increased.
In summary, here we confirmed that CT could enhance
the efficacy of ATO in treating liver cancer both in vitro
and in vivo. Our results suggest that the downregulation
Fig. 4 ATO combined with CT inhibited xenograft tumor growth on nude mice. a The 4–6-week-old male nude mice were injected subcutaneously
with 5 × 106 cells. When the subcutaneous tumors reached approximately 100 mm3, the mice were randomly assigned to four groups: control, ATO,
CT, and CT combined with ATO. Tumors were measured twice a week by a vernier caliper and the tumor volume growth curve is shown (*P < 0.01 vs.
control). b The mice were euthanized on the second day after 19 days of treatment. The excised tumors were weighed. Five mice were randomly
selected from each group and photographed using a digital camera. c The tumor weight was calculated (*P < 0.01 vs. control; #P < 0.01 ATO + CT vs.
ATO;△P < 0.01 ATO+ CT vs. CT). d The expressions of Phosphorylated- STAT3-Tyr705 and the related apoptotic proteins Bcl-2 and Bax were investigated
by immunohistochemistry. Brown, positive; blue, nuclei (×400). e Immunohistochemistry results have been quantified by statistical software Image-Pro
Plus6.0. Quantifiable results were indicated by mean optical density value
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of phosphorylated-STAT3 expression may play an im-
portant role in inducing apoptosis of Bel-7404 cells.
These results provide a new way of thinking about the
use of CT and ATO for treating liver cancer. However,
whether CT could reduce the side effects caused by
high-dose ATO in treating liver cancer remains to be
further elucidated.
Conclusions
Our study provides strong evidence of the anti-tumor
growth potency of ATO combined with CT and that
phosphorylated-STAT3 played a key role in ATO combined
with CT–induced liver cancer cell apoptosis.
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